New classification for identifying HR myeloma based on cytogenetic abnormalities
New classification for identifying HR myeloma based on cytogenetic abnormalities
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
Cancer mutation prediction using artificial intelligence
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Best practice in HRRm testing in patients with metastatic prostate cancer
Looking at real world evidence on PSA testing in prostate cancer
Stockholm3 offers a promising avenue for personalised risk-based prostate cancer diagnosis
SABCS 2023: Latest breast cancer diagnostics guidelines
Genomic testing: Awareness and effective communication between healthcare professionals and patients